Emma T van der Westhuizen

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9576196/emma-t-van-der-westhuizen-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29 papers	1,405 citations	19 h-index	31 g-index
31 ext. papers	1,637 ext. citations	7.3 avg, IF	4.28 L-index

#	Paper	IF	Citations
29	Development of Novel 4-Arylpyridin-2-one and 6-Arylpyrimidin-4-one Positive Allosteric Modulators of the M Muscarinic Acetylcholine Receptor. *ChemMedChem*, **2021**, 16, 216-233	3.7	3
28	Identification of a Novel Allosteric Site at the M Muscarinic Acetylcholine Receptor. *ACS Chemical Neuroscience*, **2021**, 12, 3112-3123	5.7	1
27	Restoring Agonist Function at a Chemogenetically Modified M Muscarinic Acetylcholine Receptor. *ACS Chemical Neuroscience*, **2020**, 11, 4270-4279	5.7	0
26	Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias. *Frontiers in Pharmacology*, **2020**, 11, 606656	5.6	7
25	Exploring use of unsupervised clustering to associate signaling profiles of GPCR ligands to clinical response. *Nature Communications*, **2019**, 10, 4075	17.4	20
24	Crystal structure of the M muscarinic acetylcholine receptor. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 26001-26007	11.5	27
23	6-Phenylpyrimidin-4-ones as Positive Allosteric Modulators at the M mAChR: The Determinants of Allosteric Activity. *ACS Chemical Neuroscience*, **2019**, 10, 1099-1114	5.7	6
22	Assessment of the Molecular Mechanisms of Action of Novel 4-Phenylpyridine-2-One and 6-Phenylpyrimidin-4-One Allosteric Modulators at the M Muscarinic Acetylcholine Receptors. *Molecular Pharmacology*, **2018**, 94, 770-783	4.3	8
21	Synthesis and Pharmacological Evaluation of Heterocyclic Carboxamides: Positive Allosteric Modulators of the M Muscarinic Acetylcholine Receptor with Weak Agonist Activity and Diverse Modulatory Profiles. *Journal of Medicinal Chemistry*, **2018**, 61, 2875-2894	8.3	10
20	Structural insights into binding specificity, efficacy and bias of a AR partial agonist. *Nature Chemical Biology*, **2018**, 14, 1059-1066	11.7	96
19	Purinergic Receptor Transactivation by the -Adrenergic Receptor Increases Intracellular Ca in Nonexcitable Cells. *Molecular Pharmacology*, **2017**, 91, 533-544	4.3	32
18	Endogenous allosteric modulators of G protein-coupled receptors. *Journal of Pharmacology and Experimental Therapeutics*, **2015**, 353, 246-60	4.7	97
17	Quantification of ligand bias for clinically relevant 2-adrenergic receptor ligands: implications for drug taxonomy. *Molecular Pharmacology*, **2014**, 85, 492-509	4.3	165
16	Effect of the emotional freedom technique on perceived stress, quality of life, and cortisol salivary levels in tension-type headache sufferers: a randomized controlled trial. *Explore: the Journal of Science and Healing*, **2013**, 9, 91-9	1.4	34
15	Relaxin family peptides and their receptors. *Physiological Reviews*, **2013**, 93, 405-80	47.9	345
14	Impedance responses reveal adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles. *PLoS ONE*, **2012**, 7, e29420	3.7	77
13	H2 relaxin is a biased ligand relative to H3 relaxin at the relaxin family peptide receptor 3 (RXFP3). *Molecular Pharmacology*, **2010**, 77, 759-72	4.3	25

12	Relaxin family peptide receptor (RXFP1) coupling to G(alpha)i3 involves the C-terminal Arg752 and localization within membrane Raft Microdomains. *Molecular Pharmacology*, **2009**, 75, 415-28	4.3	28
11	Addition of a carboxy-terminal green fluorescent protein does not alter the binding and signaling properties of relaxin family Peptide receptor 3. *Annals of the New York Academy of Sciences*, **2009**, 1160, 105-7	6.5	1
10	Roles of the receptor, the ligand, and the cell in the signal transduction pathways utilized by the relaxin family peptide receptors 1-3. *Annals of the New York Academy of Sciences*, **2009**, 1160, 99-104	6.5	8
9	Relaxin family peptide receptors--from orphans to therapeutic targets. *Drug Discovery Today*, **2008**, 13, 640-51	8.8	56
8	Insulin-Like Peptide 5 (INSL5) **2008**, 1-4		
7	Relaxin family peptide receptors--former orphans reunite with their parent ligands to activate multiple signalling pathways. *British Journal of Pharmacology*, **2007**, 150, 677-91	8.6	80
6	The relaxin family peptide receptor 3 activates extracellular signal-regulated kinase 1/2 through a protein kinase C-dependent mechanism. *Molecular Pharmacology*, **2007**, 71, 1618-29	4.3	67
5	Relaxin receptors--new drug targets for multiple disease states. *Current Drug Targets*, **2007**, 8, 91-104	3	22
4	Responses of GPCR135 to human gene 3 (H3) relaxin in CHO-K1 cells determined by microphysiometry. *Annals of the New York Academy of Sciences*, **2005**, 1041, 332-7	6.5	28
3	Inhibin-activin receptor subunit gene expression in ovarian tumors. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 1395-401	5.6	34
2	FSH-regulated gene expression profiles in ovarian tumours and normal ovaries. *Molecular Human Reproduction*, **2002**, 8, 426-33	4.4	60
1	Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product. *Biochemical and Biophysical Research Communications*, **2000**, 267, 368-72	3.4	67